The First Clinical College, Gannan Medical University, Ganzhou 341000, China.
Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China.
Asian J Androl. 2024 Jan 1;26(1):1-9. doi: 10.4103/aja202341. Epub 2023 Sep 15.
Urethral stricture is characterized by the chronic formation of fibrous tissue, leading to the narrowing of the urethral lumen. Despite the availability of various endoscopic treatments, the recurrence of urethral strictures remains a common challenge. Postsurgery pharmacotherapy targeting tissue fibrosis is a promising option for reducing recurrence rates. Although drugs cannot replace surgery, they can be used as adjuvant therapies to improve outcomes. In this regard, many drugs have been proposed based on the mechanisms underlying the pathophysiology of urethral stricture. Ongoing studies have obtained substantial progress in treating urethral strictures, highlighting the potential for improved drug effectiveness through appropriate clinical delivery methods. Therefore, this review summarizes the latest researches on the mechanisms related to the pathophysiology of urethral stricture and the drugs to provide a theoretical basis and new insights for the effective use and future advancements in drug therapy for urethral stricture.
尿道狭窄的特征为尿道管腔的慢性纤维组织形成，导致其变窄。尽管有各种内镜治疗方法，但尿道狭窄的复发仍是一个常见的挑战。针对组织纤维化的术后药物治疗是降低复发率的一个有前途的选择。虽然药物不能替代手术，但它们可用作辅助治疗以改善治疗效果。在这方面，根据尿道狭窄的病理生理学机制，已经提出了许多药物。正在进行的研究在治疗尿道狭窄方面取得了实质性进展，通过适当的临床给药方法提高药物有效性的潜力得到了强调。因此，本综述总结了与尿道狭窄病理生理学相关的机制和药物的最新研究，为尿道狭窄的药物治疗的有效使用和未来进展提供了理论依据和新的见解。
